Given the antithetical role of c/EBPα (pro-inflammatory) and c/EBPβ (anti-inflammatory), and preclinical data supporting the hypothesis of c/EBPα triggering could empower anti-tumour immunity, MTL-CEBPA (an RNA-based agonist of c/EBPα) has been recently proposed in combination with anti-PD1 for the treatments of solid tumours (Table 1). The gene discussed is PDCD1; the disease is neoplasm.